目的:探讨布地格福吸入气雾剂治疗慢性阻塞性肺疾病急性加重期患者的临床效果。方法:选取2021年1月—2023年6月就诊于镇宁布依族苗族自治县人民医院呼吸与危重症医学科的60例慢性胃炎患者为研究对象。采用随机数表法将患者分为两组，各30例。对照组患者接受布地奈德福莫特罗吸入粉雾剂治疗，观察组患者接受布地格福吸入气雾剂治疗，对两组患者临床治疗效果进行对比。结果:治疗后，观察组第1秒用力呼气容积(forced expiratory volume in one second，FEV1)、用力肺活量(forced vital capacity，FVC)、呼气峰值流速(peak expiratory flow，PEF)明显高于对照组，差异有统计学意义(P<0。05)。观察组不良反应发生率为3。33％，对照组不良反应发生率为13。33％，观察组低于对照组，差异有统计学意义(P<0。05)。观察组治疗总有效率为96。67％，对照组治疗总有效率为80。00％，观察组高于对照组，差异有统计学意义(P<0。05)。结论:与布地奈德福莫特罗吸入粉雾剂比较，布地格福吸入气雾剂在改善慢性阻塞性肺疾病急性加重期患者肺功能指标和降低不良反应发生率方面的临床效果更好。
Clinical Efficacy of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosolin the Treatment of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Objective:To explore the clinical efficacy of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosolin in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease.Method:A total of 60 patients with acute exacerbation of chronic obstructive pulmonary disease who visited the Respiratory and Critical Care Medicine Department of Zhenning Buyi and Miao Autonomous County People's Hospital from January 2021 to June 2023.The patients were divided into two groups by random number table method,with 30 patients in each group.The control group patients received treatment with Budesonide and Formoterol Fumarate Powder for Inhalation,while the observation group patients received treatment with Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosolin.The clinical treatment effects of the two groups of patients were compared.Result:After treatment,the forced expiratory volume in one second (FEV1),forced vital capacity (FVC),and peak expiratory flow rate (PEF) in the observation group were higher than those in the control group,the differences were statistically significant (P<0.05).The incidence of adverse reactions in the observation group was 3.33％,while the incidence of adverse reactions in the control group was 13.33％,the observation group was lower than the control group,the difference was statistically significant (P<0.05).The total effective rate of treatment in the observation group was 96.67％,and the total effective rate of treatment in the control group was 80.00％,the obsevation group was higher than the control group,the difference was statistically significant (P<0.05).Conclusion:Compared with Budesonide and Formoterol Fumarate Powder for Inhalation,Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosolin shows good clinical effects in improving lung function indicators and reducing the incidence of adverse reactions in acute exacerbation of chronic obstructive pulmonary disease patients.
Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation AerosolinBudesonide and Formoterol Fumarate Powder for InhalationChronic obstructive pulmonary diseaseAcute exacerbation phase
万方数据
维普
